Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

GSK (GSK) Q3 Earnings and Revenues Surpass Estimates

Glaxo (GSK) delivered earnings and revenue surprises of 15.60% and 6.14%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on CRISPR Therapeutics' (CRSP) pipeline, specifically regulatory updates on lead candidate exa-cel.

GSK (GSK) Expected to Beat Earnings Estimates: Should You Buy?

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know

In the most recent trading session, GSK (GSK) closed at $35.98, indicating a +0.5% shift from the previous trading day.

GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.

Novartis (NVS) to Report Q3 Earnings: What's in the Offing?

Investor focus is likely to be on the top and bottom-line numbers, and updates on guidance post-Sandoz spin-off when Novartis (NVS) reports its third-quarter results.

GSK (GSK) Stock Moves -1.04%: What You Should Know

In the closing of the recent trading day, GSK (GSK) stood at $36.29, denoting a -1.04% change from the preceding trading day.

5 Biotech Stocks Set to Outpace Q3 Earnings Estimates

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

GSK (GSK) Ascends While Market Falls: Some Facts to Note

In the latest trading session, GSK (GSK) closed at $36.67, marking a +0.25% move from the previous day.

Incyte (INCY) Stock Plummets 29.6% Year to Date: Here's Why

Incyte (INCY) loses 29.6% year-to-date as competition increases for Jakafi and the company suffers pipeline setbacks.

Why GSK (GSK) Outpaced the Stock Market Today

In the most recent trading session, GSK (GSK) closed at $37.56, indicating a +0.59% shift from the previous trading day.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

GSK (GSK) Surpasses Market Returns: Some Facts Worth Knowing

GSK (GSK) closed at $37.10 in the latest trading session, marking a +1.23% move from the prior day.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AstraZeneca (AZN) Settles Heartburn Drugs Lawsuits for $425M

AstraZeneca (AZN) agrees to pay $425 million to settle lawsuits related to heartburn drugs, Nexium and Prilosec.

GSK (GSK) Stock Moves -0.55%: What You Should Know

GSK (GSK) closed at $35.89 in the latest trading session, marking a -0.55% move from the prior day.

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

GSK (GSK) closed at $36.09 in the latest trading session, marking a -0.44% move from the prior day.

GSK (GSK) Stock Moves -1.14%: What You Should Know

GSK (GSK) closed the most recent trading day at $37.28, moving -1.14% from the previous trading session.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, GSK (GSK) closed at $37.71, marking a +0.75% move from the previous day.

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down

Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.